Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: J Neurochem. 2016 Dec 20;140(2):334–346. doi: 10.1111/jnc.13892

Figure 5. Lovastatin-encapsulating PLGA nanoparticles protect against EAN-induced peripheral nerve function deficits.

Figure 5

Five days prior to induction of EAN, male Lewis rats received bilateral peri-neural injections of empty- or 25% w/w lovastatin-encapsulating nanoparticles (20 mg each) as indicated. Prior to induction of EAN (open bars) or at peak of disease (closed bars) (A, B) ankle- or sciatic notch-evoked CMAP amplitudes were recorded and (C) nerve conduction velocities calculated. Data shown are the means ± SEM (n= 3-4). *, p < 0.01, two-way ANOVA with Bonferroni's post-hoc analysis.